生物
髓系细胞
干扰素
免疫学
细胞生物学
Ⅰ型干扰素
髓样
癌症研究
作者
Simone Caielli,Jacob Cardenas,Adriana A. de Jesus,Jeanine Baisch,Lynnette Walters,Jean Philippe Blanck,Preetha Balasubramanian,Cristy Stagnar,Marina Ohouo,Seunghee Hong,Lorien Nassi,Katie Stewart,Julie Fuller,Jinghua Gu,Jacques Banchereau,Tracey Wright,Raphaela Goldbach‐Mansky,Virginia Pascual
出处
期刊:Cell
[Cell Press]
日期:2021-08-01
卷期号:184 (17): 4464-4479.e19
被引量:159
标识
DOI:10.1016/j.cell.2021.07.021
摘要
Summary
Emerging evidence supports that mitochondrial dysfunction contributes to systemic lupus erythematosus (SLE) pathogenesis. Here we show that programmed mitochondrial removal, a hallmark of mammalian erythropoiesis, is defective in SLE. Specifically, we demonstrate that during human erythroid cell maturation, a hypoxia-inducible factor (HIF)-mediated metabolic switch is responsible for the activation of the ubiquitin-proteasome system (UPS), which precedes and is necessary for the autophagic removal of mitochondria. A defect in this pathway leads to accumulation of red blood cells (RBCs) carrying mitochondria (Mito+ RBCs) in SLE patients and in correlation with disease activity. Antibody-mediated internalization of Mito+ RBCs induces type I interferon (IFN) production through activation of cGAS in macrophages. Accordingly, SLE patients carrying both Mito+ RBCs and opsonizing antibodies display the highest levels of blood IFN-stimulated gene (ISG) signatures, a distinctive feature of SLE.
科研通智能强力驱动
Strongly Powered by AbleSci AI